Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Lubiprostone as a Treatment for Constipation in Parkinson's Disease
NCT00669461 · University of Arkansas · NA · terminated · last registry update 2016-12-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of recruitment” | – | Registry record, University of Arkansas |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CLCN2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-07-27Results posted on the registry: University of Louisville, Lubiprostone (NCT00844831)
- 2017-03-31Phase 3 first posted: Sucampo Pharma Americas, LLC, Lubiprostone + Placebo (NCT03097861)
- 2017-01-27Results posted on the registry: University of Michigan, Lubiprostone + Placebo (NCT01162863)
- 2017-01-05Phase 3 first posted: Sucampo Pharma Americas, LLC, Cohort 1: Lubiprostone Capsule, Fasted + Cohort 1: Lubiprostone Sprinkle Formulation, Fasted (NCT03010631)
- 2017-01-04Results posted on the registry: University of South Alabama, Lubiprostone + Placebo (NCT00746395)
- 2016-08-26Results posted on the registry: Baylor College of Medicine, LUBIPROSTONE (NCT00908076)
- 2016-08-22Results posted on the registry: Sucampo Pharma Americas, LLC, Lubiprostone + Lubiprostone (NCT00452335)
- 2016-08-01Results posted on the registry: Texas Tech University Health Sciences Center, El Paso, Lubiprostone (NCT01469819)
- 2016-05-10Phase 3 first posted: Sucampo Pharma Americas, LLC, Lubiprostone (NCT02766777)
- 2016-04-06Phase 3 first posted: Takeda, Lubiprostone + Placebo (NCT02729909)
- 2016-03-16Results posted on the registry: Sucampo Pharma Americas, LLC, Placebo + Cobiprostone (NCT00737594)
- 2016-03-15Results posted on the registry: Emory University, Lubiprostone + Placebo (NCT01170039)
- 2016-03-01Phase 3 first posted: Takeda, Placebo + Lubiprostone (NCT02695719)
- 2016-02-03Results posted on the registry: Sucampo Pharma Americas, LLC, Lubiprostone + Placebo (NCT00595946)
- 2016-01-08Phase 3 first posted: Takeda, Lubiprostone + Placebo (NCT02651155)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision